Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up

News GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London S.E.
Other stock markets
 11:35:11 2024-06-10 am EDT 		5-day change 1st Jan Change
1,621 GBX -0.49% Intraday chart for GSK plc +1.44% +11.78%
01:38pm GSK Says FDA Approved RSV Vaccine's Expanded Age Indication MT
12:30pm Moderna COVID/flu combo vaccine superior to separate shots in trial RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GSK Says FDA Approved RSV Vaccine's Expanded Age Indication
MT
Moderna COVID/flu combo vaccine superior to separate shots in trial
RE
Investors remain cautious as political instability takes over Europe
Our Logo
US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk | GSK
AQ
GSK gets FDA approval for Arexvy vax in 50-59 year olds at risk of RSV
AN
GSK: FDA approves vaccine against respiratory virus
CF
UK Stocks-Factors to watch on June 10
RE
FTSE called down amid political uncertainty in EU
AN
Indonesia ramps up fight against tuberculosis amid concerns on economic impact
RE
GSK : Goldman Sachs reaffirms its Neutral rating
ZD
Gsk PLC - FDA Approves Arexvy For Adults 50-59 At Risk
RE
GSK Secures Expanded US FDA Approval for RSV Vaccine
MT
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
BU
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
RE
GSK : DO NOT COURIER US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
PU
GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk
RE
GSK -CLINICAL DEVELOPMENT PROGRAMME CONTINUES TO EVALUATE SAFETY…
RE
GSK - FDA APPROVES EXPANDED AGE INDICATION FOR GSK'S AREXVY, FIR…
RE
GSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use
DJ
GSK : JP Morgan maintains a Sell rating
ZD
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc